Results. Alanine aminotransferase was high in 19 (26%) and HCV-RNA was positive in 46 (63%) pregnant woman. Breast milk HCV-RNA was negative in nonviremic mothers and positive in 20% of the viremic mothers. The overall rate of vertical HCV transmission was 11.9% (n ‫؍‬ 8) (95% confidence interval, 6 to 23%) if HCV-RNA was positive one or more times, but only 1.5% (n ‫؍‬ 1) (95% confidence interval, 0.1 to 9%) if HCV-RNA was permanently positive. Seven HCV-infected children did not develop antibodies to HCV, and they had a spontaneous clearance of the virus. A 10-month-old baby was HCV-RNA-positive from birth to the end of the follow-up. The genotype in each of the infants was consistent with that of their mother. The rate of HCV transmission was higher for infants of mothers with higher HCV viremia (P < 0.01) and also for infants whose mothers were HCV-RNA-positive in breast milk (P < 0.05). There were no statistically significant differences between other risk factors.
INTRODUCTION
Parenteral transmission of HCV as a result of exposure to contaminated blood products and intravenous drug use (IVDU) is well-documented. 1, 2 The rates of sexual, intrafamilial and vertical transmission seem to be low. 1, 3 However, many of those with HCV infection have no history of exposure to risk factors. 1, 3 Bortolotti et al., 4 evaluating the epidemiologic features of chronic HCV infection in children, showed that 44% of them had a mother with HCV infection. The considerable risks of vertical transmission of hepatitis B and HIV contrast with that of HCV, which varies greatly from 0 to 100%. [5] [6] [7] [8] [9] Prospective studies of HCV vertical transmission mostly report low transmission rates among unselected maternal populations but increased rates among those coinfected with the HIV or with high levels of HCV viremia. [5] [6] [7] Ohto et al. 5 have reported high HCV RNA titers in transmitting mothers. Transmission from nonviremic mothers appears to be rare. 6 The few nonviremic mothers who transmitted infection may have been misclassified as a result of HCV RNA degradation in stored maternal serum samples or intermittent viremia. HIVcoinfected mothers may result in increased titers of HCV, 10, 11 although not all studies have demonstrated an association between titers of HCV and CD4 counts. 12 Other potential risk factors such as viral genotype have been reported, 13, 14 but individual studies are too small to detect significant associations. 7, 15 Results are also conflicting with regard to any protec-tive effect of delivery by cesarean section. 8, 15 Recently Resti et al. 16 have shown a higher transmission in women who have had blood transfusions or IVDU than in women with no known risk factor for infection. HCV RNA has been demonstrated in colostrum and breast milk, 9, [17] [18] [19] but not in other studies. 20, 21 The presence of HCV RNA in breast milk may simply reflect increased maternal viral load. Analysis of existing data did not demonstrate an increased risk of vertical transmission in breast-fed children.
Some studies indicate a relationship between breastfeeding and possible transmission. 7, 17, 22 However, significant difference either in transmission rates between breast-fed and non-breast-fed 16, 17, 23 or in the duration of breast-feeding in infected or uninfected infants of mothers with high viremia levels 24 has not yet been reported.
Vertical transmission has also been documented in a number of studies, but results are conflicting. It is unclear to what extent these differences are due to variations in methodologies, or selection of maternal populations with varying levels of risk factors for HCV transmission, such as concomitant HIV infection or high levels of viremia. 5, 7, 25 Also most studies have involved small numbers, with a short duration of follow-up. The objective of this prospective study was to assess the cases of HIV negative mothers of infants regarding transmission of HCV in a long term follow-up and the role of breast-feeding in transmission.
PATIENTS AND METHODS
Patients. Sixty-three anti-HCV-positive and anti-HIV-negative pregnant women were included. Four of 63 were hepatitis B surface antigen-positive. Alanine aminotransferase (ALT) and HCV RNA in sera and peripheral blood mononuclear cells (PBMC), genotype and viremia were carried out within 1 to 2 days after delivery. Breast milk was studied in 68 samples of 35 mothers for HCV RNA and genotype. We also tested 6 breast milk samples from anti-HCV-negative mothers. Background data on age, possible route of HCV transmission, delivery mode, duration of ruptured membranes, breast-feeding and the duration of breastfeeding were obtained. Informed consent was given by each mother, and the study was approved by the ethics committee.
All 73 infants (including 3 sets of twins and 7 siblings born during the study period) of these 63 mothers were studied from 1993 to 1999. Physical examinations were performed after birth; at 2, 4, 6, 8, 10, 12, 18 and 24 months; and annually at 3, 4, 5 and 6 years. ALT, aspartate aminotransferase (AST), anti-HCV and HCV RNA (PCR) in serum and PBMC were analyzed at the same time. Infants with ALT Ͼ40 units/ml were serologically examined for other possible hepatotropic viral agents: cytomegalovirus, hepatitis A virus, anti-hepatitis A virus IgM, Epstein-Barr virus and herpes virus. Finally 25 older brothers were studied for anti-HCV and HCV RNA.
Methods. Serum samples were tested for anti-HCV antibody by enzyme-linked immunosorbent assay second or third generation (Ortho), confirmed by recombinant immunoblot assay second or third generation (Ortho). Serum aliquots of 200 L were stored at Ϫ80°C until use. PBMC were isolated from 3 ml of heparinized blood by centrifugation on Ficoll-Hypaque (Sigma-Aldrich). They were then washed twice in phosphate-buffered saline and frozen at Ϫ80°C. To facilitate taking maternal milk samples, first a manually expressed sample was given to the child after ensuring that the nipple was not damaged. Breast milk samples were centrifuged and the pellet was resuspended in phosphate-buffered saline and washed twice. Whole milk, supernatant and cells were aliquoted and frozen separately at Ϫ80°C. RNA was extracted from 200 l of serum, supernatant or whole milk following the guanidinium isothiocyanate method as described by Chomczynski et al. 26 HCV RNA was tested by reverse transcriptase-nested PCR, using primers from the 5Ј-noncoding region. Positive samples were repeated once more with new aliquots to confirm the result. In each PCR reaction a positive and negative control was included to assess the results. The genotype was tested by INNO-LiPA 27 (Innogenetics) in a new aliquot of the same positive sample. This assay can also confirm positive results. HCV RNA titer in serum was determined by the Amplicor Monitor-HCV test (Roche Diagnostic Systems, Nutley, NJ). The ALT and AST were determined (Hitachi-717/Boehringer Mannheim); ALT values above 40 units/ml were considered abnormal.
Statistical studies. Birth weight and HCV RNA (copies/ml) were reported as median Ϯ SD. For differences in the quantitative variables the t Student test or Mann-Whitney U test was used. To analyze the qualitative variables an exact Fisher's test was used (P Ͻ 0.05; significant).
RESULTS

Mothers.
Background data of 73 pregnancies of 63 mothers are given in Table 1 . In the family study 11 husbands were anti-HCV-positive, but their wives also had other risk factors (8 IVDU, 2 transfusions, 1 surgery). Seven HCV-positive mothers had liver biopsy evidence of chronic active hepatitis. Two of them were treated with interferon; one had a sustained response and the other was a nonresponder. Fifty-six mothers were ignorant of the fact that they were HCV-positive (they were routinely tested during prenatal care, with informed consent).
HCV RNA was detected in 46 (63%) pregnancies: 34 were HCV RNA-positive in sera and PBMC, 11 were positive only in sera and 1 mother was positive only in PBMC. ALT values were elevated in 19 (26%), and 18 of these were HCV RNA-positive. The mean (ϮSD) titer viremia in pregnant HCV RNA-positive mothers was 6.7 ϫ 10 5 Ϯ 1.6 ϫ 10 6 copies/ml (1.3 ϫ 10 3 to 8.8 ϫ 10 6 copies/ml). The difference between titers of viremia and genotype (genotype 1, 6.2 ϫ 10 6 Ϯ 1.2 ϫ 10 6 copies/ml vs. genotype 3a, 8.7 ϫ 10 5 Ϯ 2.6 ϫ 10 6 copies/ml) was statistically significant (P Ͻ 0.05). In 14 mothers the viremia was repeated 6 months postdelivery; in 6 cases the viremia was lower and in 8 it was higher than at the time of delivery.
Infants. Of the 73 infants 53 (72.6%) were followed from birth to 12 to 76 months of age (mean, 31.5 Ϯ 18 months), 14 (19.2%) infants were followed from birth to 6 to 12 months (mean, 8.4 Ϯ 0.8 months) and 6 (8.2%) were not included because of no follow-up, as a result of change of address or refusal by parents to return. Among the babies with the follow-up (n ϭ 67), 12 (17.9%) were delivered by cesarean section. Six (8.9%) were born prematurely. The mean birth weight was 3127 Ϯ 570 g (range, 950 to 4140 g). Forty-three (64.2%) babies were breast-fed. In 57 (85%) children the AST was elevated almost at once during follow-up, and in 29 (43.3%) the ALT value was elevated. Three children had serologic evidence of cytomegalovirus infection (positive for IgG and IgM at 2, 16 and 18 months of life). One patient required neonatal intensive care treatment and received a blood transfusion but after 4 years of follow-up remained HCV RNA-negative.
HCV markers in infants. Maternally acquired anti-HCV antibodies were detected in all infants, but at 18 months all of the infants had negative anti-HCV serologies and remained negative to the end of the follow-up, except Case 8, who had only 10 months of the follow-up and remained anti-HCV-positive. The mean age at loss of the anti-HCV was 9.2 Ϯ 3.5 months. The overall rate of vertical HCV transmission was 11.9% (n ϭ 8) (95% confidence interval, 6 to 23%) if HCV RNA was positive one or more times, 6% (n ϭ 4) (95% confidence interval, 2 to 15%) if HCV RNA was positive two or more times and 1.5% (n ϭ 1) (95% confidence interval, 0.1 to 9%) if HCV RNA was permanently positive ( Fig. 1; Table 2 ). None of them had received blood transfusion or had other risk factors. Seven of the eight neonates were breast-fed. In all cases the genotypes were determined in serum or PBMC and were the same as their mother. Two patients were siblings (Cases 2 and 7). Seven HCV RNA-positive children were followed up for 36 to 72 months and one for 10 months (Case 8). None of the seven with the longer follow-up period had seroconverted, and all children had normal ALT values. Case 8 remained anti-HCVand HCV RNA-positive, and the ALT was high. No transmission was noted in women without HCV-RNA. Twenty-five older brothers of 73 infants were seronegative for HCV.
The 8 mothers of HCV RNA-positive infants were compared with the 34 mothers who had HCV viremia but whose babies were negative for HCV RNA and with a follow-up of Ͼ6 months. There were no statistically significant differences between transfused mother (25 vs. 29%), IVDU (25 vs. 44%), unknown source of infection (50 vs. 20,6%, P ϭ 0.09), partner anti-HCVpositive (0 vs. 26,5%), genotype 1a or 1b (62 vs. 68%), infant's ALT elevation (62.5 vs. 47%), breast-feeding habits or duration, cesarean delivery (12.5 vs. 11.8%), premature delivery (0% vs. 14.7%), ruptured membranes Ͼ 4 h (12.5 vs. 8,82%) or birth weight (3361 vs.
Patterns of subsequent PCR and ALT results in viremia infants. (27) 27 (37) 19 (26) 10 (23) 20 (45) 14 (32) 46 (63) 3041g). Table 3 shows risk factors for maternal transmission of HCV. The rate of HCV transmission was higher for infants of mothers with higher HCV viremia (P Ͻ 0.01) and for whom HCV RNA was positive in breast milk (P Ͻ 0.05).
Breast-feeding study. A breast milk study was conducted in 35 anti-HCV-positive and 6 anti-HCVnegative mothers. Sixty-eight samples of colostrum and mature milk were tested for HCV RNA in cells (n ϭ 56), supernatants (n ϭ 52) and whole milk (n ϭ 56). Breast milk of the 6 anti-HCV-and HCV-RNAnegative women were HCV RNA-negative.
Thirty-five anti-HCV-positive mothers had breast milk tested. Fifteen mothers who were HCV RNAnegative in serum were also HCV RNA-negative in breast milk. Four (20%) of the 20 mothers who were HCV RNA-positive in serum were also HCV RNApositive in breast milk. Mothers with HCV RNA detected in breast milk had higher titers of HCV RNA in serum samples, although this was not statistically significant (2.6 ϫ 10 6 Ϯ 4.1 ϫ 10 6 vs. 1.3 ϫ 10 5 Ϯ 1.4 ϫ 10 5 copies/ml). Eight children had HCV RNA in the serum, and three mothers were HCV RNA-positive in breast milk; however, four mothers had no samples tested and only one sample was negative. The genotype was the same in the mother's serum, breast milk and the baby.
DISCUSSION
In this study 8 of 67 (11.9%) children of anti-HCVpositive mothers and with follow-up of Ͼ6 months showed evidence of HCV infection, but only 1.5% of children had HCV infection if HCV RNA was permanently positive. There have been conflicting reports on the rates of vertical transmission, ranging from 0 to 100%, but vertical transmission of HCV infection from HIV-negative women occurs less frequently (0 to 12%) than from HIV-positive mothers. [5] [6] [7] [8] [9] [10] [11] [13] [14] [15] , Variation between studies in overall transmission rates may therefore be partly attributed to differences in the proportion of mothers selected with HCV viremia, HIV infection or differences in the frequency and timing of infant PCR test. HCV RNA is the only method to show the infection in children without seroconversion, and some cases can clear the virus without antibody production. Therefore the infection rate depends on the follow-up duration and number of HCV RNA tests per year. No transmission was noted in HCV RNAnegative women.
The ongoing absence of HCV RNA and anti-HCV may indicate the spontaneous clearance of this virus. Transient HCV viremia in babies of infected mothers has been reported by others. 7, 13 Infants are reported to have a lower prevalence of anti-HCV than in the older population, 28 which would reflect infrequent vertical transmission and would be attributed to the low dose inoculum involved.
When we studied the transmission risk factors, no difference for mode of maternal acquisition of HCV was found between mothers who transmitted HCV to their infants and those who did not. Other potential risk factors for HCV transmission, such as viral genotype or mode of delivery, were not significant either. Genotypes 13, 14 and maternal serum ALT level before delivery 29 have been reported as risk factors. Reports are also conflicting with respect to any protective effect of delivery by cesarean section. 8, 15 Most studies on the vertical transmission of HCV do not describe the epidemiologic or the clinical situation of the pregnant women. Others studied only mothers with chronic hepatitis C or HIV coinfection. Kuroki et al. 29 suggest that active maternal liver disease may enhance vertical transmission and thus explain the high frequency of transmission in their study group. However, our mothers with high ALT had less viremia than those who were ALT-normal. Also five mothers who transmitted the virus to the children had normal ALT.
Our data did not demonstrate an increased risk of transmission for premature babies, birth weight, incidence of breast-feeding or duration of breast-feeding, as do the majority of published results. 17, 23, 24 Transmission of the virus was related to the viremia and positive breast milk HCV RNA. Our study confirmed the reported correlation between the maternal HCV RNA concentration and the rate of vertical transmis- sion. Virus load at delivery was clearly demonstrated as a risk factor of maternal transmission of HCV. [5] [6] [7] In contrast to studies indicating that HCV RNA cannot be detected in the milk of HCV RNA-positive mothers, 20, 21 our data and others 9, [17] [18] [19] show that HCV RNA was present.
In individual studies no transmission among breastfed infants has been reported, 7, 22 as well as no significant difference either in transmission rates between breast-fed and non-breast-fed infants, 17, 23 or in the duration of breast-feeding in infected vs. uninfected infants of mothers with high viremia levels. 24 The findings of these studies suggest that the overall infection risk through breast-feeding of children of HCVinfected mothers is low. The presence of HCV RNA in breast milk may simply reflect increased maternal viral load. However, not all the mothers with high viremia were breast milk-positive and in Case 4 the titer of HCV RNA was low, 1.3 ϫ 10 3 copies/ml. HCV RNA-positive breast milk should represent a high inoculum of the virus and contribute to HCV transmission. However, a low rate viremic mother has an intermittent breast milk HCV RNA positivity (20%). This makes it difficult to demonstrate this transmission route, and it is necessary to do a larger study. On the other hand seven children had a spontaneous clearance of HCV. This means that vertical transmission is not very important in our area. 
